Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP4F2 | P78329 | 2/20 | 0.33 |
| ▸ | CYP4A11 | Q02928 | 2/20 | 0.33 |
| ▸ | ATR | Q13535 | 1/20 | 0.32 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.31 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.31 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2759429 | 1.00 | CYP4F2 (0.33) | CYP4F2CYP4A11ATRGPR84FFAR1 | |
| SCHEMBL2759428 | 1.00 | CYP4F2 (0.33) | CYP4F2CYP4A11ATRGPR84FFAR1 | |
| SCHEMBL2759432 | 1.00 | CYP4F2 (0.33) | CYP4F2CYP4A11ATRGPR84FFAR1 | |
| SCHEMBL2759434 | 1.00 | CYP4F2 (0.33) | CYP4F2CYP4A11ATRGPR84FFAR1 | |
| SCHEMBL2759430 | 0.98 | CYP4F2 (0.34) | CYP4F2CYP4A11ATRALDH1A1L3MBTL1 | |
| SCHEMBL2759431 | 0.95 | ATR (0.34) | CYP4F2CYP4A11ATRALDH1A1L3MBTL1 | |
| 1,4-Butanediol SCHEMBL575671 | 0.84 | ATR (0.33) | ATRALDH1A1L3MBTL1 | |
| SCHEMBL28635310 | 0.84 | ALOX15 (0.35) | ALDH1A1L3MBTL1 | |
| SCHEMBL28624939 | 0.84 | ALOX15 (0.35) | ALDH1A1L3MBTL1 | |
| SCHEMBL28623020 | 0.84 | ALOX15 (0.35) | ALDH1A1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9024058-B2 | Ammonium fluoroalkanesulfonates and a synthesis method therefor | CENTRAL GLASS COMPANY, LIMITED (JP) | 2015-05-05 | — | — | US | disclosed |
| US-9024058-B2 | Ammonium fluoroalkanesulfonates and a synthesis method therefor | CENTRAL GLASS COMPANY, LIMITED (JP) | 2015-05-05 | — | — | US | disclosed |
| US-20120004447-A1 | Ammonium Fluoroalkanesulfonates and a Synthesis Method Therefor | CENTRAL GLASS COMPANY, LIMITED (JP) | 2012-01-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120004447-A1 | Ammonium Fluoroalkanesulfonates and a Synthesis Method Therefor | NOTUM, FAR1, PFAS | CYP4F2 401/4885CYP4A11 411/4885ATR 1495/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.